Sungcalang, Gloria T.
HRN: 27-79-67 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/19/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/20/2025
10/26/2025
IV
2.25g
Q8
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes